The prognostıc significance of blood counts in patients with hodgkin lymphoma.


Journal

Nigerian journal of clinical practice
ISSN: 1119-3077
Titre abrégé: Niger J Clin Pract
Pays: India
ID NLM: 101150032

Informations de publication

Date de publication:
Aug 2022
Historique:
entrez: 17 8 2022
pubmed: 18 8 2022
medline: 19 8 2022
Statut: ppublish

Résumé

The aim of the study was to examine the demographic, clinical features, treatment responses, and outcomes of Hodgkin lymphoma (HL) patients and to investigate the factors affecting their survival. A retrospective analysis was made of patients diagnosed with HL in our department between 2009 and 2019. Treatment regimen, treatment response, and follow-up times were recorded for all patients. Using these data, complete response (CR) rates, overall survival (OS), and progression-free survival (PFS) were calculated. The effects of parameters on survival were investigated with Cox regression analysis. Evaluation was made of 60 patients with a median age of 33.5 years [18.0-80.0] and mean follow-up duration of 29.34 ± 23.64 months. Median OS and PFS could not be reached with a mean OS of 85.6 months, and PFS of 71.7 months at the final visit. Only initial leukocyte and neurophil count were determined to have a statistically significant impact on survival (OR = 1.004; P = 0.031 vs OR = 0.996; P = 0.036). In HL patients, in addition to the many prognostic scoring systems, leukocyte and neutrophil count can be used as an independent prognostic parameter. Patients with higher leukocyte and lower neutrophil counts at the time of diagnosis should be managed more carefully.

Sections du résumé

Background and Aim UNASSIGNED
The aim of the study was to examine the demographic, clinical features, treatment responses, and outcomes of Hodgkin lymphoma (HL) patients and to investigate the factors affecting their survival.
Patients and Methods UNASSIGNED
A retrospective analysis was made of patients diagnosed with HL in our department between 2009 and 2019. Treatment regimen, treatment response, and follow-up times were recorded for all patients. Using these data, complete response (CR) rates, overall survival (OS), and progression-free survival (PFS) were calculated. The effects of parameters on survival were investigated with Cox regression analysis.
Results UNASSIGNED
Evaluation was made of 60 patients with a median age of 33.5 years [18.0-80.0] and mean follow-up duration of 29.34 ± 23.64 months. Median OS and PFS could not be reached with a mean OS of 85.6 months, and PFS of 71.7 months at the final visit. Only initial leukocyte and neurophil count were determined to have a statistically significant impact on survival (OR = 1.004; P = 0.031 vs OR = 0.996; P = 0.036).
Conclusion UNASSIGNED
In HL patients, in addition to the many prognostic scoring systems, leukocyte and neutrophil count can be used as an independent prognostic parameter. Patients with higher leukocyte and lower neutrophil counts at the time of diagnosis should be managed more carefully.

Identifiants

pubmed: 35975383
pii: NigerJClinPract_2022_25_8_1332_353793
doi: 10.4103/njcp.njcp_175_22
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1332-1337

Déclaration de conflit d'intérêts

None

Auteurs

M R Aras (MR)

Department of Hematology, University of Health Sciences Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

M Albayrak (M)

Department of Hematology, University of Health Sciences Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

A Yildiz (A)

Department of Hematology, Ministry of Health Hitit University Erol Olcok Training and Research Hospital, Corum, Turkey.

S Maral (S)

Departmanent of Hematology, Alaeddin Keykubat University Alanya Training and Research Hospital, Antalya, Turkey.

H B A Ozturk (HB)

Department of Hematology, University of Health Sciences Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

P Tiglioglu (P)

Department of Hematology, Ministry of Health Ersin Arslan Training and Research Hospital, Gaziantep, Turkey.

M Tiglioglu (M)

Department of Hematology, Ministry of Health Ersin Arslan Training and Research Hospital, Gaziantep, Turkey.

B Saglam (B)

Department of Hematology, Ministry of Health Sanliurfa Mehmet Akif Inan Training and Research Hospital, Sanliurfa, Turkey.

F Yilmaz (F)

Department of Hematology, University of Health Sciences Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH